Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large real‐world cohort
暂无分享,去创建一个
C. Strassburg | P. Brossart | M. Gonzalez-Carmona | P. Lingohr | M. Toma | G. Sarria | F. Sadeghlar | A. Jafari | N. Sommer | Christian Möhring | R. Mahn | T. Zhou | Aliki Timotheou | Adrianna Mańczak | M. Monin | Georg Feldmann | Jörg C. Kalff | M. Köksal
[1] C. Strassburg,et al. Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter? , 2022, Journal of Cancer Research and Clinical Oncology.
[2] M. Ebert,et al. FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] E. Van Cutsem,et al. MATTERHORN: phase III study of durvalumab plus FLOT chemotherapy in resectable gastric/gastroesophageal junction cancer. , 2022, Future oncology.
[4] D. Cunningham,et al. Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens. , 2022, European journal of cancer.
[5] M. Gerlinger,et al. Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study , 2022, BJS open.
[6] M. Lowery,et al. FLOT-regimen Chemotherapy and Transthoracic en bloc Resection for Esophageal and Junctional Adenocarcinoma , 2021, Annals of surgery.
[7] Z. Arık,et al. Does docetaxel matter in metastatic gastric cancer? FOLFOX versus FLOT regimens as first-line treatment , 2021, Anti-cancer drugs.
[8] A. Tannapfel,et al. Trastuzumab in combination with 5‐fluorouracil, leucovorin, oxaliplatin and docetaxel as perioperative treatment for patients with human epidermal growth factor receptor 2‐positive locally advanced esophagogastric adenocarcinoma: A phase II trial of the Arbeitsgemeinschaft Internistische Onkologie G , 2021, International journal of cancer.
[9] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[10] O. Barajas,et al. Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety , 2021, Ecancermedicalscience.
[11] F. Johnston,et al. Updates on Management of Gastric Cancer , 2019, Current Oncology Reports.
[12] M. Egger,et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial , 2019, The Lancet.
[13] Deqing Wu,et al. Retrospectively analysis of the pathology and prognosis of 131 cases of adenocarcinoma of the esophagogastric junction (Siewert type II/III) , 2017 .
[14] P. Schirmacher,et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multice , 2016, The Lancet. Oncology.
[15] Anne Berger,et al. Signet-ring cell carcinoma of the stomach: Impact on prognosis and specific therapeutic challenge. , 2015, World journal of gastroenterology.
[16] M. Ychou,et al. Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: systematic review with meta-analysis combining individual patient and aggregate data. , 2013, European journal of cancer.
[17] R. Langer,et al. Adenocarcinomas of the Esophagogastric Junction Are More Likely to Respond to Preoperative Chemotherapy than Distal Gastric Cancer , 2012, Annals of Surgical Oncology.
[18] H. Bruch,et al. Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5‐fluorouracil, oxaliplatin and docetaxel , 2012, International journal of cancer.
[19] M. Pocard,et al. The Impact of Perioperative Chemotherapy on Survival in Patients With Gastric Signet Ring Cell Adenocarcinoma: A Multicenter Comparative Study , 2011, Annals of surgery.
[20] J. Pignon,et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] P. Schlag,et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] C. V. D. van de Velde,et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. , 2006, The New England journal of medicine.
[23] H. Höfler,et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy , 2003, Cancer.
[24] H. Stein,et al. Carcinoma of the gastroesophageal junction - classification, pathology and extent of resection , 1996 .
[25] Cancer Facts & Figures 2021 , 2010 .
[26] H. Espejo,et al. [Gastric cancer]. , 1996, Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru.